Business Context and Reporting Period
Company: Bacterin International Holdings, Inc. (formerly K-Kitz, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: The Company develops, manufactures, and markets biologics products (human allografts) and medical devices (antimicrobial coatings). Key products include OsteoSponge, OsteoWrap, and OsteoLock. The Company operates through biologics and medical devices divisions.
Corporate Event: On June 30, 2010, the Company completed a reverse merger with Bacterin International, Inc., becoming the successor entity. Concurrently, it completed a private placement raising approximately $9.3 million and secured a $2.5 million credit facility with Western Technology Investment (WTI).
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $15,417,647 | $7,393,493 |
| Gross Profit | $12,053,771 | $5,075,351 |
| Gross Margin | 78.2% | 68.7% |
| Operating Loss | $(8,614,156) | $(3,624,796) |
| Net Loss | $(19,467,922) | $(4,125,742) |
| Cash and Cash Equivalents (Year End) | $327,481 | $54,155 |
| Total Assets | $15,763,615 | $10,485,890 |
| Total Liabilities | $16,382,859 | $5,801,016 |
| Stockholders' Equity (Deficit) | $(619,244) | $4,684,874 |
Debt and Liquidity: As of December 31, 2010, the Company held long-term debt of approximately $2.2 million (net of discounts) and current liabilities of $14.2 million, which included a significant warrant derivative liability of $9.7 million. The Company secured a $2.5 million credit facility with WTI in November 2010 and a revolving credit facility with Bridge Bank in January 2011.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 109% to $15.4 million, driven by a strategic shift from a distributorship model to a direct sales force model initiated in late 2009.
- Operating Expenses: Total operating expenses surged 138% to $20.7 million. Selling and marketing expenses increased 515% to $8.9 million due to the expansion of the direct sales force and increased marketing activities.
- Net Loss Expansion: Net loss widened significantly to $19.5 million (from $4.1 million). This was primarily driven by a non-cash charge of $9.2 million related to the change in warrant derivative liability, alongside increased operating costs.
- Equity Position: The Company moved from positive equity ($4.7 million) in 2009 to a deficit ($0.6 million) in 2010, largely due to the accumulated net loss and the accounting treatment of the reverse merger and warrant liabilities.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects revenue to grow in 2011 as the direct sales force matures. The Company anticipates sales and marketing expenses to rise to approximately $20 million in 2011. The Company plans to spend $4–$5 million over the next five years on facility expansion and equipment updates.
Material Risks and Contingencies:
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2010, including insufficient accounting personnel, separate inventory and accounting systems, and inadequate documentation for equity transactions.
- Liquidity: The Company relies on operating cash flows and external financing. If revenue objectives are not met, it may need to sell additional equity or seek loans, potentially causing dilution.
- Regulatory and Litigation: The Company faces ongoing litigation regarding trademark infringement (OsteoSponge) and patent infringement (minSURG). Regulatory compliance with FDA and tissue banking regulations is critical; any failure could result in product recalls or market withdrawal.
- Donor Supply: The business is highly dependent on the availability of human donor cadavers, which is subject to regulatory changes and public perception.
Investor Verification Checklist
- Warrant Liability Impact: Verify the valuation methodology for the $9.7 million warrant derivative liability and its sensitivity to stock price fluctuations.
- Internal Control Remediation: Confirm the timeline and progress of remediation efforts for the identified material weaknesses in financial reporting and inventory systems.
- Sales Force ROI: Assess the conversion rate of the expanded direct sales force against the projected $20 million in 2011 marketing spend.
- Litigation Status: Monitor the resolution of the minSURG patent infringement case and the OsteoSponge trademark disputes.
- Debt Covenants: Review the performance milestones required to draw down the second tranche of the WTI credit facility and the profitability requirements for the Bridge Bank facility expansion.